Abby B. Siegel
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis 53
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 22
- Pancreatic and Hepatic Oncology Research 17
- Colorectal Cancer Treatments and Studies 9
- Cancer Research top 2%
- Epidemiology top 2%
- Liver Disease Diagnosis and Treatment 10
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 15
-
- Ferroptosis and cancer prognosis 9
- Lung Cancer Treatments and Mutations 9
- Co-authors
- Andrew X. ZhuMasatoshi KudoRichard S. FinnJennifer J. KnoxRobert S. BrownAnn‐Lii ChengSadahisa OgasawaraBaek‐Yeol Ryoo
- Partner nations
- United StatesJapanTaiwan
In The Last Decade
Abby B. Siegel
91 papers receiving 5.7k citations
Hit Papers
Peers
Comparison fields: 5 of 112
- Hepatology 3.3k
- Oncology 2.3k
- Pathology and Forensic Medicine 1.2k
- Cancer Research 980
- Epidemiology 1.5k
Countries citing papers authored by Abby B. Siegel
This map shows the geographic impact of Abby B. Siegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abby B. Siegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abby B. Siegel more than expected).
Fields of papers citing papers by Abby B. Siegel
This network shows the impact of papers produced by Abby B. Siegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abby B. Siegel. The network helps show where Abby B. Siegel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Abby B. Siegel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 13 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 31 | |
| 7 | Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trialbreakdown → | 2022 | 127 |
| 8 | 2022 | 68 | |
| 9 | 2020 | 25 | |
| 10 | 2020 | 26 | |
| 11 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trialbreakdown → | 2019 | 1300 |
| 12 | 2015 | 24 | |
| 13 | 2015 | 22 | |
| 14 | 2014 | 25 | |
| 15 | 2013 | 73 | |
| 16 | 2012 | 127 | |
| 17 | 2011 | 11 | |
| 18 | 2011 | 130 | |
| 19 | 2009 | 312 | |
| 20 | 2007 | 76 |
About Abby B. Siegel
Abby B. Siegel is a scholar working on Hepatology, Oncology and Cancer Research, having authored 94 papers that have together received 5.8k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (53 papers), Cancer Immunotherapy and Biomarkers (22 papers), Pancreatic and Hepatic Oncology Research (17 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Liver Disease Diagnosis and Treatment (10 papers), Ferroptosis and cancer prognosis (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). The work is most often cited by research in Hepatology (3.3k citations), Oncology (2.3k citations) and Pathology and Forensic Medicine (1.2k citations). Abby B. Siegel has collaborated with scholars based in United States, Japan and Taiwan. Frequent co-authors include Andrew X. Zhu, Masatoshi Kudo, Richard S. Finn, Jennifer J. Knox, Robert S. Brown, Ann‐Lii Cheng, Sadahisa Ogasawara, Baek‐Yeol Ryoo, Stephen L. Chan and Julien Edeline. Their work appears in journals such as Journal of Clinical Oncology, Hepatology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.